In COVID-19 clinical update #114, Dr. Griffin discusses early treatment with ivermectin, procalcitonin not a reliable biomarker, vaccine in 6-11 year olds, FDA limits use of Janssen vaccine, does site of vaccine booster matter, sniffer dogs, monoclonals for hospitalized patients, risk assessment for public events, Paxlovid eligibility, and persistence of pediatric anosmia.
Become a patron of TWiV!
Links for this episode
- Effects of early treatment with Ivermectin (NEJM) 36:01
- Procalcitonin not a reliable biomarker (IDSA) 43:08
- Evaluation of vaccine in children 6 to 11 years (NEJM) 2:40
- FDA limits use of Janssen vaccine (FDA) 24:48
- Recall of B cell memory on vaccination location (Science Immunology) 26:22
- Persistence screening using sniffer dogs (Journal of Clinical Trials) 13:24
- Tixagevimab/Cilgavimab for treatment of hospitalized patients (Lancet) 28:13
- Infection detection by canine olfaction (OFID) 10:40
- Diagnostic utility to differentiate patients (IDSA) 43:55
- Prevalence of anosmia in pediatric cases (Pediatric Infectious Disease Journal) 7:22
- Risk assessment for public events (University of Texas COVID-19 Modeling Consortium) 17:03
- PAXLOVID patient eligibility screening checklist (FDA) 33:01
- PAXLOVID drug interactions (IDSA) 34:36
- Contribute to ASTMH fundraiser at PWB 48:05
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 899 48:41
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to email@example.com